News
Wells Fargo analyst Mohit Bansal maintained a Hold rating on Pfizer (PFE – Research Report) yesterday and set a price target of $28.00. The company’s shares closed yesterday a ...
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 13 Biotech Stocks with Huge Upside Potential. JPMorgan has maintained its Overweight rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) ...
Regeneron Pharmaceuticals just got a haircut from Wall Street, with JPMorgan Chase & Co. lowering its price target from $950 ...
Regeneron Pharmaceuticals saw a downgrade from Wells Fargo, slicing its stock rating from "overweight" to "equal weight" and ...
Morgan Stanley has lowered its price target on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to $755 from $958, while maintaining an Overweight rating on the stock. The revision follows what the ...
On Monday, Bernstein SocGen Group lowered the price target for Regeneron Pharma stock (NASDAQ: NASDAQ:REGN) to $750 from $896, while maintaining an Outperform rating. This adjustment follows Regeneron ...
On May 30, RBC Capital analyst Brian Abrahams downgraded Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) to Sector Perform from Outperform, and sharply reduced the stock’s price target to $662 from ...
Monday’s moves come after the S&P 500 closed out the month of May with a more than 6% gain, its best monthly performance ...
On Monday, Bernstein SocGen Group lowered the price target for Regeneron Pharma stock (NASDAQ: NASDAQ:REGN) to $750 from $896, while maintaining an Outperform rating. This adjustment follows ...
17d
Fintel on MSNWells Fargo Downgrades Regeneron Pharmaceuticals (REGN)Fintel reports that on May 30, 2025, Wells Fargo downgraded their outlook for Regeneron Pharmaceuticals (NasdaqGS:REGN) from Overweight to Equal-Weight. Analyst Price Forecast Suggests 68.40% Upside ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results